The biology and clinical evidence of microfracture in hip preservation surgery

Chadwick John Green¹,*, Aswin Beck², David Wood² and Ming H Zheng²

¹Department of Orthopaedic Surgery, Royal Perth Hospital, Perth 6000, Australia and ²Centre for Orthopaedic Research, School of Surgery, University of Western Australia, Nedlands 6009, Australia

*Correspondence to: C. J. Green, PO Box 4078, Wembley 6914, WA, Australia. E-mail: cjgreen85@gmail.com
Submitted 2 October 2015; revised version accepted 11 January 2016

ABSTRACT

The use of microfracture in hip arthroscopy is increasing dramatically. However, recent reports raise concerns not only about the lack of evidence to support the clinical use of microfracture, but also about the potential harm caused by violation of the subchondral bone plate. The biology and pathology of the microfracture technique were described based on observations in translational models and the clinical evidence for hip microfracture was reviewed systematically. The clinical outcomes in patients undergoing microfracture were the same as those not undergoing microfracture. However, the overall clinical evidence quality is poor in hips. This review identified only one study with Level III evidence, while most studies were Level IV. There were no randomized trials available for review. Repair tissue is primarily of fibrocartilaginous nature. Reconstitution of the subchondral bone is often incomplete and associated with poor quality repair tissue and faster degeneration. Subchondral bone cyst formation is associated with microfracture, likely secondary to subchondral bone plate disruption and a combination of pressurized synovial fluid and inflammatory mediators moving from the joint into the bone. There is a lack of clinical efficacy evidence for patients undergoing microfracture. There is evidence of bone cyst formation following microfracture in animal studies, which may accelerate joint degeneration. Bone cyst formation following microfracture has not been studied adequately in humans.

INTRODUCTION

Hip arthroscopy is an area under constant development, with a 6-fold increase in incidence from 2006 to 2010 [1, 2]. The indications for hip arthroscopy are also widening [3], and several publications on the use of microfracture in the hip have recently appeared in the literature. Although popular for the treatment of knee articular cartilage defects as a first line intervention to produce stem cell-based regeneration by bone marrow stimulation, we question the evidence for sustained clinical improvement following microfracture and have concerns about the potential harm caused by violation of the subchondral bone plate, the increased incidence of subchondral bone cyst formation and other pathology and adverse outcomes of autologous chondrocyte implantation following microfracture [4, 5]. Bone marrow stimulation was first presented to the British Orthopaedic Association in 1959 [6]. Pridie described the effects of drilling through the subchondral plate, making equally spaced holes to promote repair [6, 7]. Microfracture [8] and most recently the nanofracture technique [9, 10] are variations of an operation that breaches the subchondral bone plate to allow migration of stem cells and growth factors into a cartilage defect to form a ‘super clot’ and enhance repair. The reality seems to be coverage with a fibrocartilaginous scar of predominantly Type I collagen of variable quality in both the knee [11, 12], and hip [13], rather than the more durable Type II collagen of normal hyaline cartilage. Around 78 000 patients undergo microfracture annually in the United States [14, 15]. Microfracture is inexpensive and relatively easily performed arthroscopically, but more recent reports raise the concerns about the evidence to support the clinical technique traditionally in the knee and more recently in the hip [16, 17].

In light of a growing number of arthroscopic hip microfracture procedures for early cartilage loss [1, 2, 18], and the recent claim that this procedure is considered ‘safe’ and
"Efficacious" for use in the hip [19], we have reviewed the biological, translational and clinical literature of this subject. Our objective is to critically appraise the available evidence and subsequently question whether arthroscopic microfracture is a valid treatment for full thickness chondral defects in the hip.

THE BIOLOGY OF MICROFRACTURE
The osteochondral unit of diarthroidal joints consists of hyaline cartilage and the subchondral bone. The articular cartilage consists predominantly of water (65–80%), and to a lesser extent chondrocytes, proteoglycans and collagen [20]. Most of the collagen is type II and highly organized in an arcade model [21], however cartilage is avascular, aneural and alymphatic [22], making intrinsic healing problematic. The articular cartilage is firmly attached to the subchondral bone via a calcified cartilage layer. This subchondral bone can be further subdivided in two distinct entities: the subchondral bone plate composed of cortical bone and the subchondral trabecular bone [23].

The ‘superclot’ and cartilage repair
Several animal studies have evaluated the temporal healing process following microfracture [24–27]. Penetration of subchondral bone enables marrow contents to enter the joint and synovial fluid to enter the marrow space. Pluripotential mesenchymal stem cells (MSCs) and blood enter the joint and may form a clot in the cartilage defect. Growth factors and MSC are purported to play a pivotal role in the repair process [28–31].

The fraction of mononuclear cells with trilineage potential and thus MSC phenotype obtained from bone marrow is \(~0.02\%\) [32, 33]. This low number of MSCs is concerning if we assume that tissue repair is based on engrafting and differentiating of these cells. Shapiro et al. [25] showed via \(^{3}\)H-Thymidine labeling that osteochondral repair indeed occurred via differentiation of MSCs in a rabbit study. Besides the engrafting potential of MSCs, paracrine secretions and cell-to-cell contacts may also be involved in the repair process [34].

Although the timeline varies depending on the animal model investigated, the general repair events following fibrinous clot formation in a cartilage defect is similar across mammals. Initially, MSCs and capillary vessels infiltrate the fibrinous network from the periphery and fill the entire defect [25]. Differentiation of MSCs into chondrocytes and extracellular matrix formation are first evident around 10–14 days in rabbits [25, 27], but not until 6 weeks in horses [26]. The location of these initial chondrogenic foci varies from the more superficial layers of the defect [25], to below the top of the fracture hole [27, 35]. Repair tissue reaches the level of normal surrounding cartilage by around 2 weeks in rabbits [25]. The initial extracellular matrix consists of Type I collagen, with type II collagen and aggregan increasing over time starting in the deep zone, and progressing toward the surface [26]. Over time collagen fibers in the superficial zone change from a perpendicular to a tangential orientation [26, 36]. The end result however is the formation of mixed tissue types consisting of fibrocartilage (48 ± 8%), fibrous tissue (28 ± 8%) and hyaline cartilage (20 ± 6%), which was not different from untreated defects in this horse model [26, 36]. Evaluation of the microfracture technique in rabbit [24, 37, 38], dog [39] and sheep models [40] has similarly reported repair tissue of predominantly fibrocartilaginous nature. Repair tissue is overall poorly integrated with the surrounding normal cartilage [25, 39] and the optimal repair achieved by microfracture appears to be \(~8\) weeks in rabbits [24, 25]. This is followed by progressive degenerative changes within the repair tissue starting as early as 10 weeks post-operatively [25, 41]. Persistence, but no improvement of tissue quality up to 6.5 months in rabbits, and up to 12 months in horses, has also been reported [26, 38].

There is some evidence that surgical technique could influence the quality of repair tissue. Although the number of MSCs in a cartilage defect is proportional to the total exposed area following penetration of the subchondral bone plate [42], increasing the diameter of drill holes (0.9 mm versus 0.5 mm) had no effect on cartilage repair in a rabbit model [38]. Conversely, drill holes with a diameter close to physiological subchondral trabecular distance (1 mm in a sheep model) resulted in better quality repair tissue compared with larger diameter drill holes (1.8 mm) in a sheep model [43]. This could suggest that subchondral bone integrity rather than the number of MSCs determine the quality of repair tissue.

Deeper drilling (6 mm compared with 2 mm) resulted in better cartilage repair in a rabbit trochlea model and there was no difference between drilling (2 mm) or microfracture (2 mm) [37]. On the contrary, Kok et al. [44] reported no effect of hole depth and diameter on repair in an acute osteochondral talus model in goats. Differences in animal species, technique (microfracture versus drilling) and defect location make generalization difficult.

Effect of microfracture technique on subchondral bone
It has been suggested that early stages of bone marrow-derived cartilage repair depend primarily on processes occurring in the subchondral bone [35]. The proposed normal healing of the subchondral bone following microfracture observed via histology is through a combination of intramembranous bone formation and endochondral
ossification, starting in the deeper parts of the defect and progressing toward the base of defect over time, followed by the replacement of woven bone with lamellar bone [25, 35]. The repair response of the subchondral bone is incomplete and extends to a region beyond the original surgical perforation [45]. In comparison to Pridie drilling, microfracture technique reportedly maintains the integrity of the subchondral bone [46]. The word ‘integrity’ deserves attention here. A 2-cm² defect treated with six microfracture holes, diameter 2.5 mm and placed 3–4 mm apart as described in the technique, effectively removes 14.7% of the subchondral bone plate surface. Although mechanical integrity may be largely maintained initially, the structure of the subchondral plate has been altered to allow the communication between the joint fluid and the subchondral bone.

Subchondral bone plate continuity is not restored following microfracture for as long as 8 weeks to 6.5 months in animal models [25, 36, 38, 39, 41, 45, 47–49]. In addition, the repair processes following microfracture lead to a less dense subchondral bone plate, with a lower bone volume fraction, and thus increased porosity around 6 months in rabbits and sheep [38, 49]. Complete restoration however has also been observed around 18 weeks in a rabbit model [24]. These observations are important as incomplete reconstitution has been associated with more fibrous cartilage repair and increased degeneration of repair tissue [25, 48].

Surgical technique can influence the subchondral bone structure. Microfracturing with an arthroscopic awl has largely replaced drilling procedures as it produces no thermal necrosis of the bone [46]. Although thermal necrosis is indeed avoided, microfracture induced acute fracturing and compaction of bone surrounding the holes 24 h after creation in a rabbit model [50]. This sealed off the holes from the subchondral marrow and caused osteonecrosis [50]. Although it was suggested that the design of the custom-made awl could have contributed to the observation [50], compaction has also been reported using traditional arthroscopic awls [51].

Compared with drilling, microfracture lead to more residual holes and a coarser subchondral bone structure in a rabbit model [45]. Deeper drilling caused bone repair and remodeling over a greater region and restored the bone volume fraction to a greater extent than superficial drilling [45]. Drill holes with a diameter close to physiological subchondral trabecular distance (1 mm in a sheep model) resulted in improved restoration of the subchondral bone plate and subarticular spongiosa [43], an observation which has lead to the current clinical practice of nanofracture [9, 10].

### Subchondral bone pathology

Bone tissue overgrowth into the chondral compartment is an important concern in marrow-stimulation procedures [4, 13, 52], and has also been observed in animal models [36, 41, 45, 49, 53–56]. Despite this observation, its recognition as pathology has been largely ignored [36, 53, 55]. For example, the current practice of removing the calcified cartilage prior to microfracture induced more bone formation in the chondral compartment in a horse model [53]. This observation was not further discussed, and the authors recommended removal of the calcified cartilage to achieve better integration of repair tissue with the subchondral bone [53].

### Subchondral bone cyst formation

Bone cyst formation following microfracture in animal models is common [45, 47, 49, 53, 56]. Similar to bone overgrowth, this observation has received little attention and its significance has been questioned [47, 53]. The reported prevalence of subchondral bone cyst formation following microfracture in animal studies is as high as 92% [56], and appears to be more prevalent when the subchondral bone structure was specifically evaluated [45, 49, 56], suggesting a general underreporting of this important finding in the literature.

Besides creating a pathway for MSCs to migrate into the defect, penetration of the subchondral bone plate also allows synovial fluid to migrate into the subchondral bone space. Persistent communication between the joint and subchondral bone cysts via microfracture holes has been shown [56], and surgical penetration of the subchondral bone was essential to induce subchondral bone cyst formation in a horse model [57].

Both fluid pressure and flow have been shown to cause bone resorption in rat models of prosthetic loosening [58, 59]. Pressurized fluid can induce bone lysis either due to displacement of trabeculae directly by the fluid [60], or it may decrease perfusion and oxygen supply followed by osteocyte death and osteolysis [61]. Cox et al. [62] demonstrated via a computational model that fluid pressure resulted in an irregularly shaped cavity which became rounded and obtained a sclerotic bone rim after removal of the pressurized fluid. Cyst formation due to osteocyte death resulted in round cystic lesions surrounded by sclerosis [62]. Although the contribution of fluid pressure in cyst formation following microfracture technique has not been investigated specifically, in a recent sheep study we observed cyst formation with an irregular outline following microfracture technique [56], see Figs. 1. In the same study, we also observed high numbers of osteoclasts and Howship’s lacunae at the periphery of the cystic lesions.
Von Rechenberg et al. [63] showed an upregulation of IL-1 and IL-6 mRNA in clinical cases of subchondral bone cysts in horses and concluded that both cytokines were associated with pathological bone resorption in cystic lesions. In an osteochondral autograft sheep model, Benazzo et al. [64] showed similarly an association between subchondral cyst formation and increased IL-1 and TNF-alfa levels in the synovial fluid. In addition, these cytokines have also been demonstrated within arthroplasty pseudomembranes in aseptic periprosthetic osteolysis [65], and their role in bone resorption has also been established via in vitro experiments [66, 67].

In summary of the preclinical evidence, marrow-stimulating techniques result in poorly integrated fibrocartilaginous repair tissue with deterioration occurring over time. Microfracture breaches the subchondral bone plate and leads to incomplete restoration of its structure at best. Smaller diameter drill holes seem to improve cartilage repair, possibly due to decreased disturbance of the subchondral bone structure. Microfracture weakens the trabecular bone structure and frequently leads to subchondral bone pathology including upward migration of the subchondral bone plate and subchondral bone cyst formation.

METHODS FOR CLINICAL REVIEW
To investigate the clinical evidence of microfracture, we identified original studies in humans looking specifically at arthroscopic hip microfracture, or patients that had microfracture as a treatment variable. Review articles were read, but not included in the analysis, as they were not original studies. Single case reports were excluded due to the high potential for bias. In vitro studies or studies not including humans were excluded.

On the 20th August 2015, a literature search was carried out using the MEDLINE and EMBASE databases with the following keywords: microfracture, marrow stimulation, hip, acetabulum and acetabular. There were 48 MEDLINE and 121 EMBASE hits, and after reading the abstracts and removing duplicate data we identified 12 original studies [13, 18, 68–77], of which there were 0 RCTs. A search of Cochrane Reviews for the keywords ‘hip’ and ‘microfracture’ returned zero results.

Reading through the reference lists of the review articles and the identified original studies manually identified three additional original studies, which involved microfracture for full thickness cartilage defects [78–80].

There were 15 original articles available for review. One cohort study (Level III evidence) [18], two case–control studies (Level IV evidence) and 12 case series (Level IV evidence). Studies with more than 10 microfracture patients [13, 18, 71, 72, 74–77, 79, 80] are presented in Table I and discussed below. Studies with less than 10 patients undergoing microfracture [68–70, 73, 78] are presented in Table II. We decided that these studies were grossly underpowered and have not discussed their results specifically in text.

THE CLINICAL OUTCOMES OF MICROFRACTURE
Microfracture in hips
A prospective cohort study by Domb et al. [18] found no significant difference in mean patient reported outcome (PRO) scores, between patients undergoing microfracture and those that did not at 2 years. However, PRO scores for both groups improved significantly from baseline—likely due to the confounding effect of the other procedures undertaken as indicated. The microfracture group had more pain on a 0–10 (10 being the worst) Visual Analogue Scale (3.63 versus 2.82, \( P = 0.02 \)) and less satisfaction with their arthroscopy (\( P < 0.05 \)). Patients undergoing

Fig. 1. Micro computed tomography 3D illustrations of subchondral bone cyst formation in the femoral condyle of sheep, 26 weeks following microfracture, with persistent communications with the microfracture hole (scale bar = 1 mm).
microfracture had full-thickness chondral defects in the hip
(Outerbridge IV), compared with a matched control group
without full thickness chondral defects (Outerbridge I–
III), which is a potential source of bias for the results. In
addition, patients in both groups underwent additional
intra-operative procedures as indicated (e.g. acetabulo-
plasty, femoral neck osteoplasty, labral tear repairs or de-
bridement). Though not the largest of the studies
identified, Domb et al. had the greatest number of patients
undergoing microfracture (baseline \( n = 99 \), follow-up
\( n = 79 \)). All patients underwent post-operative physio-
therapy, continuous passive motion therapy, and a period of
protected weight bearing (8 weeks for the microfracture
group, 2 weeks for the control group).

A case–control study by McDonald et al. [74] looked at
young male athletes and return to professional sports fol-
lowing hip arthroscopy. Return to sport was not signifi-
cantly improved by microfracture at 36 months compared
with no microfracture (77 versus 84%, respectively,
\( P > 0.05 \)) [74]. There were 39 patients in the microfracture
group and 81 unmatched controls. There were many
indications for the initial hip arthroscopy (e.g. labral tears,
cartilage defects, loose bodies, femoracetabular impinge-
ment, ligamentum teres or capsule pathology) and subse-
sequently many confounding intra-operative procedures
offered for both case and control groups; in addition to
microfracture for Outerbridge IV defects in the case group.

A later case-control study by McDonald et al. [75],
again in young male athletes, aimed to assess the level of
function returning players achieved post-hip arthroscopy.
The control group comprised other professional athletes
from the league that were matched with cases based on
pre-operative sports statistics (games played, wins, losses,
performance statistics, etc). The controls did not undergo
hip arthroscopy. Though the reported results were positive,
with 82% of patients undergoing hip arthroscopy with
microfracture returning to professional sports at the same
level as matched controls [75], there was a significant loss
to follow up of 47%. In addition, confounding intra-opera-
tive procedures were undertaken as part of the hip arthro-
scopy (femoral neck osteoplasty, acetabuloplasty,
chondroplasty, labral tear repair, reconstruction or debride-
ment, as indicated).

The largest two case series studies were by Byrd and
Jones [79] and Haviv et al. [71]. Byrd and Jones [79]
looked at 220 consecutive patients undergoing hip arthros-
copy for cam impingement. Pre- versus post-operative
modified Harris Hip Scores (mHHS) were recorded with a
mean follow up of 16 months. All patients improved from
baseline with a mean increase in the mHHS of +20, how-
ever there was no difference in improvement for patients
undergoing microfracture (\( n = 58 \)) and those who did not
[79]. Similarly, Haviv et al. [71] looked at 381 consecutive
patients undergoing hip arthroscopy for cam impingement.
There was a 54% loss to follow up at 22 months for all pa-
tients, and only 29 patients available for review who had
microfracture. The patients remaining in the study at 22
months all showed significant improvement from baseline
on functional scores (mHHS and Non-Arthritic Hip Score—
NAHS). Those having microfracture had better a
mean NAHS at 22 months than those not having micro-
fracture (\( P < 0.05 \)), though were not significantly
improved on the mHHS at 22 months [71]. Confounding
intra-operative procedures were undertaken in both studies
as indicated (femoral neck osteoplasty, correction of pincer
impingement, chondroplasty, labral tear debridement or
radio-frequency ablation) [71, 79].

No significant differences in post-operative functional
scores between patients undergoing microfracture and
those not undergoing microfracture were reported in the
other Table I case series studies, due largely to their meth-
odology and lack of a comparative group [13, 72, 77, 80].
Like Haviv et al., they were also confounded by other intra-
operative procedures, or different rehabilitation regimes,
and had potential reporting bias from high losses to follow
up.

In a second look arthroscopic study of 20 microfracture
patients by Karthikeyan et al. [13] 19 out of 20 patients
(95%) had a mean defect fill of 96% (89–100%). Two pa-
tients were biopsied, and their histology showed repair
with predominantly fibrocartilage [13]. There was no sta-
tical improvement in the NAHS for these 20 patients,
from pre-original arthroscopy to 17 months post-original
arthroscopy to post-second-look arthroscopy at 21 months
\(+55, +54, +73, \text{ respectively, } P > 0.05\).

Finally, a comparative case series by Fontana and de
Girolamo [76], followed one series of cases undergoing
microfracture and another series of cases undergoing au-
tologous matrix-induced chondrogenesis (AMIC), for
Outerbridge Grade III-IV chondral defects. Each series had
statistical improvement in pre- versus post-operative
mHHS scores, and the AMIC series was statistically better
on mHHS at 5 years compared with the microfracture series
\( \sim 82 \text{ versus } \sim 72, P = 0.001 \) [76]. The lack of a con-
trol group and that patients were not randomly selected
for each of the series limits the methodology and validity
of the results seen. There were also confounding intra-op-
erative procedures for both groups (femoral neck osteo-
plasty, acetabuloplasty, or labral tear repair, as indicated)
and selection bias as the microfracture series included
more men (71 versus 51%, \( P = 0.017 \)) and had a higher in-
cidence of cam lesions (\( P = 0.034 \)).
Table I. Summary of original articles with greater than 10 patients undergoing microfracture for full thickness cartilage defects in the hip

| Study (level of evidence)a | Design (comparison group) | Patient numbers (hip numbers) | Mean age in years (Baseline) | Follow-Up (mo) | Post op Limits | Mean MFx Defect Size (mm²) | Outcomeb | Comments |
|---------------------------|--------------------------|-------------------------------|------------------------------|---------------|---------------|---------------------------|----------|----------|
| Domb et al [18] (III)     | Matched-Cohort (yes)     | MFx 99 Control N/A            | 44, in each group (59%)      | 24            | Hip brace, variable protected weight bearing depending on group, physio-therapy & CPM | 189 ± 98 | Mean PRO MFx versus Control (2 year) not significantly different Visual Analog Scale for Pain (0–10, 10 is most severe pain) - MFx (2 year) = 3.63 - Control (2 year) = 2.82 (P = 0.02) Patient Satisfaction - MFx (2 year) = 7.2 - Control (2 year) = 8.0 (P 0.05) | MFx patients had Outerbridge IV, and had 8 weeks of protected weight bearing Non-MFx patients had Outerbridge III or less, and had 2 weeks of protected weight bearing |
| McDonald et al [74] (IV)  | Case-control (yes)       | MFx 39 (39) Control 81 (94)   | 29 (100%)                    | 36            | No significant difference in return to play post op: - MFx = 77% - Control = 84% (P > 0.05) | 162      | The control group is not matched to the case group. Non-MFx patients had only 2 weeks of protected weight bearing. MFx patients had Outerbridge IV grades, Non-MFx patients were Outerbridge I–III |
| McDonald et al [75] (IV)  | Case-control (yes)       | MFx = 32                     | 31 (100%)                    | 24            | As per above | 119      | - 82% of participants returned to professional sport - 18% (3 participants) did not return to professional sport. All had acetabular MFx, rim trimming, femoral neck osteoplasty and labral repair | MFx patients had Outerbridge IV grades. Players were excluded if they had previous ipsilateral hip surgery, or were retiring from professional sport. ‘Matched-controls’ did not undergo surgery |
| Study (level of evidence) | Design (comparison group) | Patient numbers (hip numbers) | Mean age in years (%male) | Follow Up (mo) | Mean MFx Defect Size ($\text{mm}^2$) | Post op Limits | Outcome $^b$ | Comments |
|--------------------------|---------------------------|-------------------------------|--------------------------|--------------|------------------------------------|----------------|-------------|----------|
| Byrd and Jones [79] (IV) | Case Series (no)          | 220 (227)                     | 33 (69%) MFx = 58        | No           | NR                                 | WBAT with crutches, physio-therapy, impact loading avoided for 3 months. MFx Patients PWB 2 months | Mean mHHS improvement (range)  
  - MFx: +20 (-17, +58)  
  - Non-MFx: +20 (-17, +60)  
  No difference in outcomes for MFx versus non-MFx | All patients with cam, or cam-pincer impingement included. 20 Patients with pincer-only impingement excluded. Microfractured patients had Outerbridge IV grades  
  1 patient converted to total hip arthroplasty, 8 months post arthroscopy. |
| Haviv et al. [71] (IV)  | Case Series (no)          | 381                           | 166 (170) MFx = NR 29    | No           | <300                               | Weight bearing as tolerated, physio-therapy, Jog/Run 6 weeks if non-MFx versus 14 weeks if MFx | Mean mHHS pre versus post-op  
  - MFx: +73 -> 88 ($P = 0.04$)  
  - Non-MFx: +70 -> 83 ($P = 0.004$)  
  Mean NAHS pre versus post-op  
  - MFx: +70 -> 90 ($P < 0.001$)  
  - Non-MFx: +68 -> 81 ($P = 0.003$)  
  At second look:  
  - 19/20 pts (95%) had a mean defect fill of 96% ±7%  
  - 2 athletes biopsied repair scar chiefly fibrocartilage  
  - 4 patients had labrocapsular adhesions  
  - 7 patients had catching sensation from cartilage | Patients with advanced arthritis (i.e. Tönnis grade 3) on preop radiography were excluded. Significant improvement in all groups compared with baseline. MFx significantly better than non-MFx only at 22 months ($P < 0.05$) |
| Karthikeyan et al. [13] (IV) | Case Series (no)          | Nb. 285 patients in original dataset | 20 MFx patients had repeat arthroscopy | 37 (80%) No | 17 ± 11 154 | Immediate CPM 24–48 h, physio-therapy, Foot-flat non-weight bearing 6 weeks, full weight bearing by 8 weeks | At second look:  
  - 19/20 pts (95%) had a mean defect fill of 96% ±7%  
  - 2 athletes biopsied repair scar chiefly fibrocartilage  
  - 4 patients had labrocapsular adhesions  
  - 7 patients had catching sensation from cartilage | All patients had full thickness acetabular chondral defect in superior or antero-superior acetabular zones & a labral tear. Indication for repeat scope was either persistent or reoccurring |
| Study (level of evidence) | Design (comparison group) | Patient numbers (hip numbers) | Mean age in years (male) | Follow Up (mo) | Mean MFx Defect Size (mm²) | Post op Limits | Outcome | Comments |
|--------------------------|---------------------------|-----------------------------|-------------------------|---------------|--------------------------|---------------|---------|----------|
| **Stafford et al.** [72] (IV) | Case Series (no) | 54 | 43 | 24 (58%) | 28 | NR | Physiotherapy, toe-touch weight bearing for 4 weeks with crutches post op. | overgrowth at MFx site, requiring fibrochondroplasty NAHS pre versus post-MFx (17 months) versus post second-look (21 months) = +55 - 54 - 73 (P > 0.05) Mean mHHS (pain) pre versus 28 months post-op (all patients) = 21.8 versus 35.8 (P < 0.001) Mean mHHS (function) pre versus 28 months post-op (all patients) = 40 versus 43.6 (P < 0.001) No significant difference in mHHS for 1 versus 3 years post op. (P = 0.44) | symptoms of FAL Possible selection bias. The authors acknowledge that the same surgeon did the MFx & also the assessment of defect fill on second look arthroscopy. No MFx or fibrin as cause for significant improvement in pain and function scores. Areas of subchondral bone treated with MFx + Fibrin were still endowed by 20% loss to followup |
| **Philippon et al.** [80] (IV) | Case Series (no) | 122 | 90 | 41 (45%) | 27.6 | NR | Physiotherapy, partial weight bearing and CPM for 6–8 weeks. Anti-rotation bolster for 10 days post op. | No difference in mean mHHS for MFx vs non-MFx patients (81 versus 86, P = 0.2). Mean mHHS improved from baseline for all patients (P < 0.001) 10 patients had undergone a THA at a mean of 16 months post arthroscopy – these patients were significantly older (58 versus 39 years), and had lower mean pre-op mHHS (47 versus 60, P < 0.001) | 47% loss to follow up amongst microfracture patients. Only Charnley A, (see Charnley et al., 1972) patients included in this study – i.e. patients where a single hip joint is the only cause of mobility disability. Subsequent selection bias. Patients undergoing MFx of both the acetabulum and femoral |

(continued)
| Study (level of evidence) | Design (comparison group) | Patient numbers (hip numbers) | Mean age in years (percent male) | Follow-up (mo) | Mean MFx Defect Size (mm²) | Post op Limits | Outcome | Comments |
|---------------------------|---------------------------|-------------------------------|-------------------------------|----------------|-----------------------------|---------------|---------|----------|
| Horibberger et al. [77] (IV) | Case Series (yes) | 20 (drawn from a larger pool of 150 patients having arthroscopy for FAI) | 47.3 (80%) | 36 | NR | Physiotherapy 6–8 weeks. Non-MFx: full weight bearing. MFx: PWB 4–6 weeks | 10/19 patients had undergone a THA at a mean of 1.4 years post index arthroscopy. For nine patients without THA, mean NAHS pre-op versus 36 months (P = 0.004) (No significant difference between MFx and non-MFx groups). | The 20 selected patients had Outerbridge II or more. Authors acknowledged confounding from associated surgery as likely cause for improvement from baseline for all patients. |
| Fontana and de Girolamo [76] (IV) | Comparative Case Series (yes) | 3 years | MFx 77 AMIC 70 | 39 (71%) | 60 | MFx 370 AMIC 350 | Physiotherapy, CPM day 1, RoM exercises, non-weight bearing 4 weeks, partial weight bearing 7 weeks | mHHS pre-op. MFx = 47.1 AMIC = 44.7 (P = 0.01) mHHS 1 year MFx = ~82 AMIC = ~82 (P > 0.05) mHHS Syr MFx = ~72 AMIC = ~82 (P < 0.001) All patients at 5 years improved compared with baseline (P < 0.001) | Included patients had: Outerbridge Grade III & IV chondral lesions, and less than Tönnis Grade II degenerative changes. Patients not randomized to groups. More males in MFx group (P = 0.017) Substantial loss to follow-up at 5 years, more so in MFx group. 6 patients (7.8%) in MFx group required THA at a mean of 3.2 years post-op. |

aBased on the Oxford Centre for Evidence-based Medicine - Levels of Evidence (see http://www.cebm.net/cebm-levels-of-evidence/).
bAll papers included associated surgery; most papers had multiple associated surgeries in addition to microfracture. Associated surgeries as part of 'hip arthroscopy' included any of: femoral neck osteoplasty, acetabuloplasty, chondroplasty, labral tear repair or debridement, ligamentum teres debridement, capsule plication or release, fibrin glue use and/or loose body removal, as indicated. NR = not recorded; MFx = microfracture; PWB = partial weight bearing; CPM = continuous passive motion; PRO (Patient Reported Outcome Score) is the average of the following scores: Modified Harris Hip Score, Non-Arthritic Hip Score, Hip Outcome Score Activities of Daily Living Subscale, Hip Outcome Score Sport Specific Subscale [18]. mHHS = Modified Harris Hip; NAHS = Non-arthritic hip Score; THA = Total hip arthroplasty; AMIC = Autologous matrix induced chondrogenesis; FAI = femoroacetabular impingement.
Table II. Summary of original articles with 10 or less patients undergoing microfracture for full thickness cartilage defects in the hip

| Study (level of evidence)a | Design (comparison group) | Patient numbers (hip numbers) | Baseline | Follow-up | Mean age in years (% male) | Follow up (months) | Mean MFx defect size (mm²) | Post-op. limits | Outcomeb | Comments |
|---------------------------|---------------------------|-------------------------------|----------|-----------|----------------------------|-------------------|---------------------------|----------------|----------|----------|
| Amenabar and O’Donnell [78] (IV) | Case Series (no) | 36 (44) | 16 (NR) | MFx N = 8 | 22 (100%) | Yes | NR | Full weight bearing as tolerated | mHHS pre vs post-op = 84 - 98 (P < 0.05) | NAHS pre- versus post-op = 86 - 97 (P < 0.05) | Outcomes post microfracture not measured specifically |
| Singh et al. [70] (IV) | Case Series (no) | 24 (27) | 24 (27) | MFx = 6 | 22 (100%) | Yes | <300 | Avoidance of impact loading for 6 weeks | Mean mHHS pre- versus 2 years post-op (all patients) = 86 versus 97 (P = 0.05) | Mean NAHS pre- versus 2 year post-op (all patients) = 81 versus 99 (P = 0.05) | Participants were all Professional AFL football players, all with sub-acute groin pain, not responding to conservative treatment. 1 player who did not return had most severe lesion found on arthroscopy – rim lesion with 40% cartilage loss, an unstable os acetabula, and cam impingement. Patient underwent femoro-plasty, chondroplasty, excision of unstable os acetabula and labral tear, and MFx. Microfractured patients had Outerbridge IV grades |
| Study (level of evidence) | Design (comparison group) | Patient numbers (hip numbers) | Mean age in years (months) | Follow up (months) | Mean MFx defect size (mm$^2$) | Post-op. limits | Outcome | Comments |
|--------------------------|---------------------------|------------------------------|---------------------------|-------------------|-----------------------------|----------------|----------|----------|
| Boykin et al [73] (IV)   | Case Series (no)          | 21 (23) MFx N = 9            | 17 (NR) MFx N = 8         | 28 (100%)         | Yes                         | NR            | Hip brace, variable protected weight bearing and CPM depending on if MFx occurred, Physiotherapy, hydro-therapy | mHHS mean change (95%CI, P value) = +16.4 (2–30, P < 0.05) HOSs mean change (95%CI, P value) = +20.8 (6–35, P = 0.01) No difference in improvement for those undergoing MFx versus those not undergoing MFx | MFx patients had Outerbridge IV, and had 8 weeks of protected weight bearing Non-MFx patients had Outerbridge III or less, and had 3 weeks PWB 2 patients (10%) progressed to THA |
| Byrd and Jones [68] (IV) | Case Series (no)          | 9                            | 51 (56%) MFx = 3          | 24 NR             | Weight bearing as tolerated. MFx Patients protected-weight bearing 10 weeks | Mean mHHS pre versus post-op MFx +5.23 -> 88.6 Non-MFx +47 -> 48.8 3 MFx patients returned to high levels of function (martial arts, horse riding, fitness activities) as per the authors | Not adequately powered to detect a difference |
| Philippon et al [69] (IV) | Case Series (no)         | 9                            | 37 (56%) MFx = 3          | 20 163            | Physiotherapy, toe-touch weight bearing and CPM for 8 weeks (based on Steadman et al, 2002) | At second look arthroscopy: Average defect fill was 91% - 1 patient had only 25% fill, however also had diffuse Grade IV chondral defects, and had femoral head resurfacing at the time of the second look arthroscopy. - 3 patients had capsulolabral adhesions | 9 patients drawn from a larger case series. Possible subsequent selection bias |

a Based on the Oxford Centre for Evidence-based Medicine - Levels of Evidence (see http://www.cebm.net/cebm-levels-of-evidence/).
b All papers included associated surgery; most papers had multiple associated surgeries in addition to microfracture. Associated surgeries as part of ‘hip arthroscopy’ included any of: femoral neck osteoplasty, acetabuloplasty, chondroplasty, labral tear repair or debridement, ligamentum teres debridement, capsule plication or release, fibrin glue use, and/or loose body removal, as indicated.

NR = not recorded; MFx = microfracture; PWB = partial weight bearing; CPM = continuous passive motion; mHHS = Modified Harris Hip; NAHS = Non-arthritic hip Score; HOSs = Hip outcome score – sport specific subscale; THA = Total hip arthroplasty.
Microfracture in knees

Despite the popularity, there is increasing evidence that also questions the value of microfracture in knees. Recent reviews by Goyal et al., and Bert, report that the long-term clinical results of microfracture are no better than those for patients who do not have microfracture [16], and that microfracture is not without risks [17].

Goyal et al. [16] reviewed all Level I and Level II studies on PubMed and concluded that in the short-term, for young patients with small lesion sizes and low post-operative demands, microfracture was associated with good clinical outcomes. However, ‘beyond 5 years post-operatively, treatment failure after microfracture could be expected regardless of lesion size’ [16]. The only Level I study directly comparing microfracture with debridement of unstable edges in this review, concluded no improvement at 10 years for patients undergoing microfracture compared with those having debridement [81].

Bert [17] highlighted the risks associated with microfracture; that disruption of the subchondral plate predisposes the bone to the development of subchondral cysts and fragile or brittle bone [17, 82, 83], subsequently accelerating osteoarthritis.

THE REFLECTION OF BIOLOGICAL PROCESSES ON CLINICAL OUTCOME

Most of our basic science understanding of post-microfracture repair physiology comes from animal models [24–27, 36, 50, 51]. Although similar findings are reported in humans who undergo second look arthroscopy with repair tissue biopsy and histopathology [11, 13], the timing of repair stages is likely to be different as it is for different animals. The animal models suggest that microfractured chondral defects are filled with a fibrocartilaginous scar of predominantly Type I collagen [36], consisting of limited and poorly organized chondrocytes [25], which poorly integrate with surrounding cartilage [25], and start to degenerate at a variable time period of less than 1 year, depending on the animal model used [25, 38]. Progressive degeneration is then noted over time [25].

Once fractured the subchondral bone plate will attempt auto-repair or reconstitution through endochondral and intramembranous bone formation, however this frequently fails [25, 36, 38, 39, 41, 45, 47–49]. Articular repair tissue located on a compromised, unsupportive base is then prone to failure. This presents with increased fibrocartilage repair tissue [48], and increased degeneration of this repair tissue [25].

In addition, damage to the subchondral plate during microfracture, or any other marrow stimulating technique, exposes the subchondral bone to the joint space and if reconstitution of the subchondral bone fails, can lead to fragility and development of subchondral bone cysts [17, 82, 83]. This bone fragility is proposed to accelerate degenerative changes affecting the joint [17]. Infiltration of cytokines and metalloproteinases through the microfracture holes into the bone deep to the subchondral plate [63, 64], and increased fluid pressure causing osteolysis may be implicated in subchondral bone cyst formation [58–61]. ‘Collateral damage’ to the subchondral plate from the impact of the microfracture awl may also cause localized osteonecrosis [50, 51].

Finally, elevation of the subchondral plate during repair [36], bone tissue overgrowth into the chondral compartment or joint [4, 13, 36, 45, 49, 52–56] and osteophyte formation [55], are all reported but understudied complications of microfracture and damage to the subchondral plate.

The translation of preclinical findings to the clinical situation remains difficult. However, a recent analysis of five failures following marrow stimulation techniques in early osteoarthritic knees has shown fibrocartilaginous repair tissue and incomplete restoration of the subchondral bone [84]. Interestingly, three out of these five cases had a nearly normal macroscopic appearance based on the International Cartilage Repair Society Visual Assessment, underlining the importance of evaluation of the entire osteochondral unit.

THE CURRENT ISSUES WITH THE CLINICAL EVIDENCE ON MICROFRACTURE IN HIPS

Most studies had small [13, 18, 72, 74, 75, 77] or very small [68–70, 73, 78] sample sizes, with the majority of the data underpowered to detect smaller effect sizes. The largest studies were from Haviv et al. [71] (381 patients enrolled, 29 had microfracture), Byrd and Jones [79] (220 patients enrolled, 58 had microfracture), Fontana and de Girolamo [76] (144 patients enrolled, 77 had microfracture) and Philippon et al. [80] (122 patients enrolled, 47 had microfracture). In general, these larger studies had high losses to follow up [71, 76, 80], or disparity in loss to follow up, with microfractured patients having twice the loss the follow-up of non-microfractured patients [76, 80]. This increased loss to follow up introduces a reporting bias that may be in favor of patients having microfracture, especially for the studies with disparity in loss to follow up.

Numerous studies gathered data from predominantly young, male and athletic patients, with small cartilage defect sizes, introducing a selection bias and a difficulty in generalizing or extrapolating findings to general patient population who present with cartilage defects. Of the 15 original studies included in this review, the authors
observed mean ages of <50 years for 13 studies [13, 18, 69, 70–76, 78–80], less than 30 years for five studies [70, 72–74, 78], predominantly male participants (>75%) in seven studies [13, 70, 71, 73–75, 78], exclusive inclusion of athletes in five studies [70, 73–75, 78] and mean defect size to undergo microfracture of <200 mm² in five studies [13, 18, 69, 74, 75]. The mean cartilage defect size was not recorded for six studies [68, 72, 73, 78–80], which may mask the level of bias introduced.

No long-term data were available for our review of microfracture in the hip, most studies had a short follow up of 2 years or less [13, 18, 68, 69–71, 75, 79]. Only one study achieved medium-term follow up of 5 years [76]. The lack of long-term data is problematic. Microfracture in knees shows improvement in patient function in the short-term, but not long-term efficacy [16]. Basic science suggests a worsening of outcomes long-term as subchondral bone degeneration is accelerated by microfracture through the subchondral plate [17, 82, 83]. We hypothesize that long-term data may show a worsening of outcomes for patients undergoing microfracture, compared with controls not undergoing microfracture. If this is true, the technique is unethical and should be abandoned.

The highest level of clinical evidence identified, for the use of microfracture in hip arthroscopy, was Level III, and this was only achieved by one study [18]. All other studies were of Level IV evidence. Microfracture generally did not improve functional outcomes any more so than what was observed in comparison groups not undergoing microfracture [18, 71, 74, 77, 79, 80]. Patient function improved from baseline in all studies, regardless of whether microfracture occurred or not. This is likely due to confounding factors, such as the other intra-operative procedures undertaken (e.g. femoral neck osteoplasty, acetabuloplasty, chondroplasty, labral tear repair or debridement, ligamentum teres debridement, capsule plication or release, and/or loose body removal, as indicated) as part of the umbrella-treatment term of ‘hip arthroscopy’. Confounding intra-operative treatments and variable rehabilitation programs were found in all of the studies reviewed.

There were numerous limitations across the studies, and the effect of bias and confounding on the results of the clinical data should not be underestimated. Only three studies had a control group [18, 74, 75], the rest were case series without a control [13, 68, 69, 70–73, 78–80].

CONCLUSION
Given the developing evidence for subchondral cyst formation and acceleration of degenerative changes following microfracture in animal models, we recommend that surgeons avoid any procedure that involves disruption of the subchondral plate until long-term safety data are available in humans. It is important to appreciate how well patients, who do not have microfracture, do following hip arthroscopy with the other associated surgeries undertaken. It seems the addition of microfracture, although technically easy, is not justified based on the available data. To test the effect of microfracture as a treatment for full thickness cartilage defects in the hip, an adequately powered, long-term, randomized controlled trial (specifically comparing microfracture with a control group of patients not undergoing microfracture) is required. Such a design would also have to adjust for confounding surgeries and rehabilitation programs.

CONFLICT OF INTEREST STATEMENT
None declared.

REFERENCES
1. Bozic KJ, Chan V, Valone FH, et al. Trends in hip arthroscopy utilization in the United States. J Arthroplasty 2013;28(8 Suppl):140–3.
2. Montgomery SR, Ngo SS, Hobson T, et al. Trends and demographics in hip arthroscopy in the United States. Arthroscopy 2013;29:661–5.
3. Yen Y-M, Kocher MS. Chondral lesions of the hip. Microfracture and chondroplasty. Sports Med Arthosc Rev 2010;18:83–9.
4. Minas T, Gornall AH, Rosenberger R, et al. Increased failure rate of autologous chondrocyte implantation after previous treatment with marrow stimulation techniques. Am J Sports Med 2009;37:902–8.
5. Pestka JM, Bode G, Salzmann G, et al. Clinical outcome of autologous chondrocyte implantation for failed microfracture treatment of full-thickness cartilage defects of the knee joint. Am J Sports Med 2012;40:325–31.
6. Pridie KH, Gordon G. A method of resurfacing osteoarthritic knee joints. J Bone Joint Surg Br 1959;41:618–9.
7. Insall J. The Pridie debridement operation for osteoarthritis of the knee. Clin Orthop Relat Res 1974;101:61–7.
8. Steadman JR, Rodkey WG, Singleton SB, et al. Microfracture technique for full-thickness chondral defects technique and clinical results. Oper Tech Orthop 1997;7:300–4.
9. Benthien JP, Behrens P. Reviewing subchondral cartilage surgery: considerations for standardised and outcome predictable cartilage remodelling. A Technical Note. Int Orthop 2013;37:2139–45.
10. Benthien JP, Behrens P. Nanofractured autologous matrixinduced chondrogenesis (NAMIC(c))—further development of collagen membrane aided chondrogenesis combined with subchondral needling; a technical note. Knee 2015;22:411–5.
11. Bae DK, Yoon KH, Song SJ. Cartilage healing after microfracture in osteoarthritic knees. Arthroscopy 2006;22:367–74.
12. Freedman KB, Coleman SH, Olenac C, et al. The biology of articular cartilage injury and the microfracture technique for the treatment of articular cartilage lesions. Semin Arthroplasty 2002;13:202–9.
Evidence of microfracture in hip preservation surgery

13. Karthikeyan S, Roberts S, Griffin D. Microfracture for acetabular chondral defects in patients with femoroacetabular impingement: results at second-look arthroscopic surgery. Am J Sports Med 2012;40:2725–30.

14. Montgomery SR, Foster BD, Ngo SS, et al. Trends in the surgical treatment of articular cartilage defects of the knee in the United States. Knee Surg Sports Traumatol Arthros 2014;22:2070–5.

15. McCormick F, Harris JD, Abrams GD, et al. Trends in the surgical treatment of articular cartilage lesions in the United States: an analysis of a large private-payer database over a period of 8 years. Arthroscopy 2014;30:222–6.

16. Goyal D, Keyhani S, Lee EH, et al. Evidence-based status of microfracture technique: a systematic review of Level I and II studies. Arthroscopy 2013;29:1579–88.

17. Bert JM. Abandoning microfracture of the knee: has the time come? Arthroscopy 2015;31:501–5.

18. Domb BG, Gupta A, Dunne KF, et al. Microfracture in the hip: results of a matched-cohort controlled study with 2-year follow-up. Am J Sports Med 2015;43:1865–74.

19. Lienert JJ, Rodkey WG, Steadman JR, et al. Microfracture techniques in hip arthroscopy. Oper Tech Orthop 2005;15:267–72.

20. Bhosale AM, Richardson JB. Articular cartilage: structure, injuries and review of management. Br Med Bull 2008;87:77–95.

21. Benninghoff A. Form und Bau der Gelenkknorpel in ihren Beziehungen zur Funktion. II. Der Aufbau des Gelenknorpels in seinen Beziehungen zur Funktion. Z Zellforsch Mikros Anat Histoch 1925;2:783–862.

22. Buckwalter JA, Mankin HJ. Articular cartilage. Part 1: tissue design and chondrocyte–matrix interactions. J Bone Joint Surg Am 1997;79:600–11.

23. Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci 2010;1192:230–7.

24. Meachim G, Roberts C. Repair of the joint surface from subarticular tissue in the rabbit knee. J Anat 1971;109(Pt 2):317–27.

25. Shapiro F, Koide S, Glimcher MJ. Cell origin and differentiation in the repair of full-thickness defects of articular cartilage. J Bone Joint Surg Am 1993;75:532–53.

26. Frisbie DD, Oxford JT, Southwood L, et al. Early events in cartilage repair after subchondral bone microfracture. Clin Orthop Relat Res 2003;215–27.

27. Chevrier A, Hoemann CD, Sun J, et al. Temporal and spatial modulation of chondrogenic foci in subchondral microdrill holes by chitosan-glycerol phosphate/blood implants. Osteoarthritis Cartilage 2011;19:136–44.

28. Indrawattana N, Chen G, Tadokoro M, et al. Growth factor combination for chondrogenic induction from human mesenchymal stem cell. Biochem Biophys Res Commun 2004;320:914–9.

29. Fortier LA, Barker JU, Strauss EJ, et al. The role of growth factors in cartilage repair. Clin Orthop Relat Res 2011;469:2706–15.

30. Freyria AM, Mallein-Gerin F. Chondrocytes or adult stem cells for cartilage repair: the indisputable role of growth factors. Injury 2012;43:259–65.

31. Gardner OF, Archer CW, Alini M, et al. Chondrogenesis of mesenchymal stem cells for cartilage tissue engineering. Histol Histopathol 2013;28:23–42.

32. Kastrinaki MC, Sidiroopoulos P, Roche S, et al. Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis 2008;67:741–9.

33. de Girolamo I, Bertolini G, Cervellin M, et al. Treatment of chondral defects of the knee with one step matrix-assisted technique enhanced by autologous concentrated bone marrow: in vitro characterisation of mesenchymal stem cells from iliac crest and subchondral bone. Injury 2010;41:1172–7.

34. Procop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 2009;17:939–46.

35. Chevrier A, Hoemann CD, Sun J, et al. Chitosan-glycerol phosphate/blood implants increase cell recruitment, transient vascularization and subchondral bone remodeling in drilled cartilage defects. Osteoarthritis Cartilage 2007;15:316–27.

36. Frisbie DD, Trotter GW, Powers BE, et al. Arthroscopic subchondral bone plate microfracture technique augments healing of large chondral defects in the radial carpal bone and medial femoral condyle of horses. Vet Surg 1999;28:242–55.

37. Chen H, Hoemann CD, Sun J, et al. Depth of subchondral perforation influences the outcome of bone marrow stimulation cartilage repair. J Orthop Res 2011;29:1178–84.

38. Marchand C, Chen G, Tran-Khanh N, et al. Microdrilled cartilage defects treated with thrombin-solidified chitosan/blood implant regenerate a more hyaline, stable, and structurally integrated osteochondral unit compared to drilled controls. Tissue Eng Part A 2012;18:508–19.

39. Breinan HA, Martin SD, Hsu HP, et al. Healing of canine articular cartilage defects treated with microfracture, a type-II collagen matrix, or cultured autologous chondrocytes. J Orthop Res 2000;18:781–9.

40. Ergele C, Endres M, Neumann K, et al. Formation of cartilage repair tissue in articular cartilage defects pretreated with microfracture and covered with cell-free polymer-based implants. J Orthop Res 2009;27:1353–60.

41. Dorotka R, Bindreiter U, Cucchiarini M, et al. Small subchondral drill holes improve marrow stimulation of articular cartilage defects. Am J Sports Med 2014;42:2741–50.

42. Kok AC, Tuijthof GJ, den Dunnen S, et al. Effect of different bone marrow stimulation techniques (BSTs) on MSCs mobilization. J Orthop Res 2013;31:1814–9.

43. Eldracher M, Orth P, Cucchiariini M, et al. Small subchondral drill holes improve marrow stimulation of articular cartilage defects. Clin Orthop Relat Res 2013;471:3653–62.

44. Chen H, Chevrier A, Hoemann CD, et al. Characterization of subchondral bone repair for marrow-stimulated chondral defects and its relationship to articular cartilage resurfacing. Am J Sports Med 2011;39:1731–40.

45. Steadman JR, Rodkey WG, Rodrigo JJ. Microfracture: surgical technique and rehabilitation to treat chondral defects. Clin Orthop Relat Res 2001;391:S362–9.

46. Hoemann CD, Hurtig M, Rossomacha E, et al. Chitosan-glycerol phosphate/blood implants improve hyaline cartilage repair
in ovine microfracture defects. J Bone Joint Surg Am 2005; 87:2671–86.
48. Hoemann CD, Sun J, McKeer MD, et al. Chitosan-glycerol phosphate/blood implants elicit hyaline cartilage repair integrated with porous subchondral bone in microdrilled rabbit defects. Osteoarthritis Cartilage 2007; 15:78–89.
49. Orth P, Goebl L, Wolfram U, et al. Effect of subchondral drilling on the microarchitecture of subchondral bone: analysis in a large animal model at 6 months. Am J Sports Med 2012; 40:828–36.
50. Chen H, Sun J, Hoemann CD, et al. Drilling and microfracture lead to different bone structure and necrosis during bone-marrow stimulation for cartilage repair. J Orthop Res 2009; 27:1432–8.
51. Fortier LA, Cole BJ, Mcllwraith CW. Science and animal models of marrow stimulation for cartilage repair. J Knee Surg 2012; 25:3–8.
52. Brown WE, Potter HG, Marx RG, et al. Magnetic resonance imaging appearance of cartilage repair in the knee. Clin Orthop Relat Res 2004; 422:214–23.
53. Frisbie DD, Morisset S, Ho CP, et al. Effects of calcified cartilage on healing of chondral defects treated with microfracture in horses. Am J Sports Med 2006; 34:1824–31.
54. Ertgelet C, Neumann K, Endres M, et al. Regeneration of ovine articular cartilage defects by cell-free polymer-based implants. Biomaterials 2007; 28:S570–80.
55. McIlwraith CW, Frisbie DD, Rodkey WG, et al. Evaluation of intra-articular mesenchymal stem cells to augment healing of microfractured chondral defects. Arthroscopy 2011; 27:1552–61.
56. Beck A, Murphy DJ, Zheng MH. Treatment of articular cartilage defects with AMIC and microfracture leads to extensive subchondral bone cyst formation in a sheep model. Unpublished.
57. Ray CS, Baxter GM, McIlwraith CW, et al. Development of subchondral cystic lesions after articular cartilage and subchondral bone damage in young horses. Equine Vet J 1996; 28:225–32.
58. Skripitz R, Aspemberg P. Pressure-induced periarticular osteolysis: a rat model. J Orthop Res 2000; 18:481–4.
59. Fahlgren A, Bostrom MP, Yang X, et al. Fluid pressure and flow as a cause of bone resorption. Acta Orthop 2010; 81:508–16.
60. Landells JW. The bone cysts of osteoarthritis. J Bone Joint Surg Br 1953; 35B:643–9.
61. Aspemberg P, Van der Vis H. Migration, particles, and fluid pressure. A discussion of causes of prostatic loosening. Clin Orthop Relat Res 2008; 352:75–80.
62. Cox LG, Lagemaat MW, van Donkelaar CC, et al. The role of pressurized fluid in subchondral bone cyst growth. Bone 2011; 49:762–8.
63. von Rechenberg B, Leutenegger C, Zlinsky K, et al. Upregulation of mRNA of interleukin-1 and -6 in subchondral cystic lesions of four horses. Equine Vet J 2001; 33:143–9.
64. Benazzo F, Cadosi M, Cavani F, et al. Cartilage repair with osteochondral autografts in sheep: effect of biophysical stimulation with pulsed electromagnetic fields. J Orthop Res 2008; 26:631–42.
65. Jiranek WA, Machado M, Jasty M, et al. Production of cytokines around loosened cemented acetabular components. Analysis with immunohistochemical techniques and in situ hybridization. J Bone Joint Surg Am 1993; 75:863–79.
66. Gowen M, Mundy GR. Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J Immunol 1986; 136:2478–82.
67. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A 1993; 90:11924–8.
68. Byrd T, Jones KS. Osteoarthritis caused by an inverted acetabular labrum: radiographic diagnosis and arthroscopic treatment. Arthroscopy 2002; 18:741–7.
69. Philippon MJ, Schenker ML, Briggs KK, et al. Can microfracture produce repair tissue in acetabular chondral defects? Arthroscopy 2008; 24:46–50.
70. Singh P, O’Donnell JM. The outcome of hip arthroscopy in Australian Football League players: a review of 27 hips. Arthroscopy 2010; 26:743–9.
71. Haviv B, Singh PJ, Takla A, et al. Arthroscopic femoral osteochondroplasty for cam lesions with isolated acetabular chondral damage. J Bone Joint Surg Br 2010; 92B:629–33.
72. Stafford GH, Bunn JR, Villar RN. Arthroscopic repair of delaminated acetabular articular cartilage using fibrin adhesive. Results at one to three years. Hip Int 2011; 21:744–50.
73. Boykin RE, Patterson D, Briggs KK, et al. Results of arthroscopic labral reconstruction of the hip in elite athletes. Am J Sports Med 2013; 41:2296–301.
74. McDonald JE, Herzog MM, Philippon MJ. Return to play after hip arthroscopy with microfracture in elite athletes. Arthroscopy 2013; 29:330–5.
75. McDonald JE, Herzog MM, Philippon MJ. Performance outcomes in professional hockey players following arthroscopic treatment of FAI and microfracture of the hip. Knee Surg Sports Traumatol Arthrosc 2014; 22:915–9.
76. Fontana A, de Girolamo L. Sustained five-year benefit of autologous matrix-induced chondrogenesis for femoral acetabular impingement-induced chondral lesions compared with microfracture treatment. Bone Joint J 2015; 97B:628–35.
77. Horisberger M, Brunner A, Herzog RF. Arthroscopic treatment of femoral acetabular impingement in patients with preoperative generalized degenerative changes. Arthroscopy 2010; 26:623–9.
78. Amenabar T, O’Donnell J. Return to sport in Australian Football League footballers after hip arthroscopy and midterm outcome. Arthroscopy 2013; 29:1188–94.
79. Byrd T, Jones KS. Arthroscopic femoroplasty in the management of cam-type femoroacetabular impingement. Clin Orthop Relat Res 2009; 467:739–46.
80. Philippon MJ, Briggs KK, Yen Y-M, et al. Outcomes following hip arthroscopy for femoroacetabular impingement with associated chondrolabral dysfunction. Minimum two-year follow-up. J Bone Joint Surg Br 2009; 91B:16–23.
81. Gudas R, Gudaite A, Mickevicius T, et al. Comparison of osteochondral autologous transplantation, microfracture, or debridement techniques in articular cartilage lesions associated with anterior cruciate ligament injury: a prospective study with a 3-year follow-up. Arthroscopy 2013; 29:89–91.
82. Gudas R, Simonaityte R, Cekanauskas E, et al. A prospective, randomized clinical study of osteochondral autologous transplantation versus microfracture for the treatment of
osteochondritis dissecans in the knee joint in children. *J Pediatr Orthop* 2009;29:741–8.

83. Knutsen G, Drogset JO, Engebretsen L, et al. A randomized trial comparing autologous chondrocyte implantation with microfracture findings at five years. *J Bone Joint Surg Am* 2007;89:2105–12.

84. Kaul G, Cucchiarini M, Remberger K, et al. Failed cartilage repair for early osteoarthritis defects: a biochemical, histological and immunohistochemical analysis of the repair tissue after treatment with marrow-stimulation techniques. *Knee Surg Sports Traumatol Arthrosc* 2012;20:2315–24.